{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:10Z","timestamp":1781697370844,"version":"3.54.5"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    To evaluate the cost\u2013effectiveness of stapokibart compared with dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP) from the healthcare system perspective in China. The focus is on assessing the economic viability of biologic treatments in managing CRSwNP, particularly when conventional treatments and\/or surgery fail to provide sufficient relief.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A decision tree Markov model was developed to assess the cost\u2013effectiveness of stapokibart and dupilumab. Clinical data from multiple trials were used, and a matching-adjusted indirect comparison was conducted to account for differences in patient populations across studies. Sensitivity analysis was performed to evaluate the robustness of the model results under varying assumptions.\n                    <jats:bold>Results:<\/jats:bold>\n                    The study results indicate that stapokibart offers a clear economic advantage over dupilumab. It both lowers treatment costs and enhances patients' quality of life. Sensitivity analysis shows that stapokibart remains cost-effective at the threshold of one to three-times China\u2019s per capita GDP, demonstrating strong economic viability in the Chinese healthcare context.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The study demonstrates that stapokibart is a cost-effective treatment option for CRSwNP compared with dupilumab. It offers significant improvements in patient outcomes and is economically viable under the prevailing healthcare budget in China, providing valuable insights for policy-makers and healthcare providers.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0189","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:25:21Z","timestamp":1779279921000},"source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost\u2013effectiveness analysis"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9283-4863","authenticated-orcid":false,"given":"Jingran","family":"Yang","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ren","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8905-4567","authenticated-orcid":false,"given":"Fengyuan","family":"Xie","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Shao","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-9536","authenticated-orcid":false,"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_7_3_2","first-page":"221","article-title":"China guidelines for the diagnosis and treatment of chronic rhinosinusitis (2024)","volume":"60","author":"Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Rhinology Group of Otorhinolaryngology Head and Neck Surgery Branch of Chinese Medical Association","year":"2025","unstructured":"Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Rhinology Group of Otorhinolaryngology Head and Neck Surgery Branch of Chinese Medical Association, Jiang Y China guidelines for the diagnosis and treatment of chronic rhinosinusitis (2024). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 60(3), 221\u2013249 (2025).","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"e_1_3_7_4_2","volume-title":"Clinical Study on the Improvement of Olfactory Dysfunction in Patients with Chronic Rhinosinusitis without Nasal Polyps Using Nasal Three-Injection Therapy [Dissertation]","author":"Li D","year":"2023","unstructured":"Li D. Clinical Study on the Improvement of Olfactory Dysfunction in Patients with Chronic Rhinosinusitis without Nasal Polyps Using Nasal Three-Injection Therapy [Dissertation]. Guangzhou University of Chinese Medicine, Guangzhou, China (2023)."},{"key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert C","year":"2021","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J. Asthma Allergy. 14, 127\u2013134 (2021).","journal-title":"J. Asthma Allergy."},{"issue":"9","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya N","year":"2019","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 129(9), 1969\u20131975 (2019).","journal-title":"Laryngoscope"},{"issue":"11","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1080\/03007995.2020.1815683","article-title":"Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen S","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Garcia D, Rosta E. Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis. Curr. Med. Res. Opin. 36(11), 1913\u20131926 (2020).","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"e_1_3_7_8_2","first-page":"117","article-title":"Current status of symptom distress in patients with chronic rhinosinusitis with nasal polyps and its relationship with negative emotions and quality of life","volume":"31","author":"Liu YB","year":"2024","unstructured":"Liu YB, Liu YC, Sun AX Current status of symptom distress in patients with chronic rhinosinusitis with nasal polyps and its relationship with negative emotions and quality of life. Dang Dai Hu Shi 31(8), 117\u2013121 (2024).","journal-title":"Dang Dai Hu Shi"},{"issue":"1","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","article-title":"Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada","volume":"19","author":"Yong M","year":"2023","unstructured":"Yong M, Kirubalingam K, Desrosiers MY, Kilty SJ, Thamboo A. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada. Allergy Asthma Clin. Immunol. 19(1), 90 (2023).","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"12","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong M","year":"2021","unstructured":"Yong M, Wu YQ, Howlett J, Ballreich J, Walgama E, Thamboo A. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int. Forum Allergy Rhinol. 11(12), 1626\u20131636 (2021).","journal-title":"Int. Forum Allergy Rhinol."},{"issue":"6","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/jpm12060951","article-title":"Cost-utility analysis of dupilumab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Italy","volume":"12","author":"De Corso E","year":"2022","unstructured":"De Corso E, Furneri G, Salsi D Cost-utility analysis of dupilumab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Italy. J Pers Med. 12(6), 951 (2022).","journal-title":"J Pers Med."},{"issue":"1","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas GA","year":"2021","unstructured":"Scangas GA, Wu AW, Ting JY Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope 131(1), E26\u2013E33 (2021).","journal-title":"Laryngoscope"},{"issue":"11","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2025.12515","article-title":"Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 Randomized Clinical Trial","volume":"334","author":"Shen S","year":"2025","unstructured":"Shen S, Yan B, Wang M Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 Randomized Clinical Trial. JAMA 334(11), 962\u2013972 (2025).","journal-title":"JAMA"},{"issue":"10209","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase III trials","volume":"394","author":"Bachert C","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase III trials. Lancet 394(10209), 1638\u20131650 (2019).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000529918","article-title":"Chinese expert consensus on the use of biologics in patients with chronic rhinosinusitis","volume":"85","author":"Hong HY","year":"2023","unstructured":"Hong HY, Zhang Y, Wang TC Chinese expert consensus on the use of biologics in patients with chronic rhinosinusitis. ORL J. Otorhinolaryngol. Relat. Spec. 85(3), 128\u2013140 (2023).","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"e_1_3_7_16_2","unstructured":"National Health Commission of the People's Republic of China. Statistical bulletin on the development of China's health undertaking in 2023. National Health Commission website. (2024). (Accessed: 10 July 2025). https:\/\/file.m12333.cn\/upfile\/download\/bf66337f-795a-c925-d6fc-efa4f99495c8.pdf"},{"issue":"3","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.21037\/atm-22-65","article-title":"A comprehensive investigation of the demographics, treatments, comorbidities, and disease burden of chronic rhinosinusitis with nasal polyposis patients: a descriptive analysis","volume":"10","author":"Zhao Q","year":"2022","unstructured":"Zhao Q, Yu L, Jin P A comprehensive investigation of the demographics, treatments, comorbidities, and disease burden of chronic rhinosinusitis with nasal polyposis patients: a descriptive analysis. Ann. Transl. Med. 10(3), 150 (2022).","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"e_1_3_7_18_2","first-page":"1201","article-title":"Application of matching-adjusted indirect comparison in medical research","volume":"22","author":"Liu YX","year":"2022","unstructured":"Liu YX, Wang RT, Li GW. Application of matching-adjusted indirect comparison in medical research. Chin. J. Evid. Based Med. 22(10), 1201\u20131205 (2022).","journal-title":"Chin. J. Evid. Based Med."},{"issue":"6","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. (6), \u2013691 (1997).","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_3_7_20_2","unstructured":"World Health Organization. Life tables by country: China. Global Health Observatory data repository. (2025). (Accessed: 10 July 2025). https:\/\/apps.who.int\/gho\/data\/view.main.60340?lang=en"},{"key":"e_1_3_7_21_2","first-page":"2878648","article-title":"The efficacy and cost-effectiveness of umeclidinium\/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease","volume":"2022","author":"Gong Y","year":"2022","unstructured":"Gong Y, Lin C, Jin Y The efficacy and cost-effectiveness of umeclidinium\/vilanterol versus tiotropium in symptomatic patients with chronic obstructive pulmonary disease. Can. Respir. J. 2022, 2878648 (2022).","journal-title":"Can. Respir. J."},{"key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"1345942","DOI":"10.3389\/fimmu.2023.1345942","article-title":"Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer","volume":"14","author":"Lin YT","year":"2024","unstructured":"Lin YT, Wang C, He XY Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer. Front. Immunol. 14, 1345942 (2024).","journal-title":"Front. Immunol."},{"key":"e_1_3_7_23_2","volume-title":"China guidelines for pharmacoeconomic evaluations (2020 edition)","year":"2020","unstructured":"China guidelines for pharmacoeconomic evaluations (2020 edition). China Medical Science Press, Beijing, China (2020)."},{"key":"e_1_3_7_24_2","unstructured":"National Bureau of Statistics of China. National data. National Bureau of Statistics of China website. (2025). (Accessed: 10 July 2025). http:\/\/data.stats.gov.cn\/"},{"issue":"4","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10198-021-01384-z","article-title":"Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life","volume":"23","author":"Cai D","year":"2022","unstructured":"Cai D, Shi S, Jiang S Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur. J. Health Econ. 23(4), 607\u2013615 (2022).","journal-title":"Eur. J. Health Econ."},{"key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert C","year":"2021","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M Burden of disease in chronic rhinosinusitis with nasal polyps. J. Asthma Allergy 14, 127\u2013134 (2021).","journal-title":"J. Asthma Allergy"},{"issue":"5","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2500\/aap.2022.43.220048","article-title":"Clinical and economic burden of chronic rhinosinusitis with nasal polyposis: a US administrative claims analysis","volume":"43","author":"Peters AT","year":"2022","unstructured":"Peters AT, Bengtson LGS, Chung Y Clinical and economic burden of chronic rhinosinusitis with nasal polyposis: a US administrative claims analysis. Allergy Asthma Proc. 43(5), 435\u2013445 (2022).","journal-title":"Allergy Asthma Proc."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:19:54Z","timestamp":1781695194000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2025-0189"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0189","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e250189"}}